{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T10:24:52Z","timestamp":1771669492202,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2019R1A2C1004582"],"award-info":[{"award-number":["NRF-2019R1A2C1004582"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s12272-021-01366-y","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T17:02:27Z","timestamp":1640365347000},"page":"114-121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects"],"prefix":"10.1007","volume":"45","author":[{"given":"Nam-Tae","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang\u2011Keun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pureum","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye-Jung","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Jeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung\u2011Woo","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choon-Gon","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4162-1981","authenticated-orcid":false,"given":"Seok-Yong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,24]]},"reference":[{"issue":"4","key":"1366_CR1","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1365-2125.2005.02448.x","volume":"60","author":"JW Bae","year":"2005","unstructured":"Bae JW, Kim HK, Kim JH, Yang SI, Kim MJ, Jang CG, Park YS, Lee SY (2005) Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 60(4):418\u2013422. https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02448.x","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1366_CR2","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1365-2125.2010.03853.x","volume":"71","author":"JW Bae","year":"2011","unstructured":"Bae JW, Choi CI, Jang CG, Lee SY (2011a) Effects of CYP2C9*1\/*13 on the pharmacokinetics and pharmacodynamics of meloxicam. Br J Clin Pharmacol 71(4):550\u2013555. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03853.x","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"1366_CR3","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/aps.2011.100","volume":"32","author":"JW Bae","year":"2011","unstructured":"Bae JW, Choi CI, Kim MJ, Oh DH, Keum SK, Park JI, Kim BH, Bang HK, Oh SG, Kang BS, Park HJ, Kim HD, Ha JH, Shin HJ, Kim YH, Na HS, Chung MW, Jang CG, Lee SY (2011b) Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics. Acta Pharmacol Sin 32(10):1303\u20131308. https:\/\/doi.org\/10.1038\/aps.2011.100","journal-title":"Acta Pharmacol Sin"},{"issue":"9","key":"1366_CR4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.5414\/cp201467","volume":"50","author":"JW Bae","year":"2012","unstructured":"Bae JW, Choi CI, Lee HI, Lee YJ, Jang CG, Lee SY (2012) Effects of CYP2C9*1\/*3 and *1\/*13 on the pharmacokinetics of losartan and its active metabolite E-3174. Int J Clin Pharmacol Ther 50(9):683\u2013689. https:\/\/doi.org\/10.5414\/cp201467","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"11","key":"1366_CR5","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s12272-020-01293-4","volume":"43","author":"JW Bae","year":"2020","unstructured":"Bae JW, Oh KY, Yoon SJ, Shin HB, Jung EH, Cho CK, Lim CW, Kang P, Choi CI, Jang CG, Lee SY, Lee YJ (2020) Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide. Arch Pharm Res 43(11):1207\u20131213. https:\/\/doi.org\/10.1007\/s12272-020-01293-4","journal-title":"Arch Pharm Res"},{"issue":"9","key":"1366_CR6","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s12272-018-1070-y","volume":"41","author":"JY Byeon","year":"2018","unstructured":"Byeon JY, Kim YH, Kim SH, Lee CM, Jung EH, Chae WK, Jang CG, Lee SY, Lee YJ (2018) The influences of CYP2C9*1\/*3 genotype on the pharmacokinetics of zolpidem. Arch Pharm Res 41(9):931\u2013936. https:\/\/doi.org\/10.1007\/s12272-018-1070-y","journal-title":"Arch Pharm Res"},{"issue":"2","key":"1366_CR7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12272-018-1099-y","volume":"42","author":"JY Byeon","year":"2019","unstructured":"Byeon JY, Lee CM, Lee YJ, Kim YH, Kim SH, Jung EH, Chae WK, Lee YJ, Jang CG, Lee SY (2019) Influence of CYP2D6 genetic polymorphism on pharmacokinetics of active moiety of tolterodine. Arch Pharm Res 42(2):182\u2013190. https:\/\/doi.org\/10.1007\/s12272-018-1099-y","journal-title":"Arch Pharm Res"},{"issue":"12","key":"1366_CR8","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1111\/dme.14176","volume":"37","author":"L Chen","year":"2020","unstructured":"Chen L, Li JH, Kaur V, Muhammad A, Fernandez M, Hudson MS, Goldfine AB, Florez JC (2020) The presence of two reduced function variants in CYP2C9 influences the acute response to glipizide. Diabet Med 37(12):2124\u20132130. https:\/\/doi.org\/10.1111\/dme.14176","journal-title":"Diabet Med"},{"key":"1366_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-021-01357-z","author":"CK Cho","year":"2021","unstructured":"Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2021a) Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele. Arch Pharm Res. https:\/\/doi.org\/10.1007\/s12272-021-01357-z","journal-title":"Arch Pharm Res"},{"key":"1366_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-021-01361-3","author":"CK Cho","year":"2021","unstructured":"Cho CK, Park HJ, Kang P, Moon S, Lee YJ, Bae JW, Jang CG, Lee SY (2021b) Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes. Arch Pharm Res. https:\/\/doi.org\/10.1007\/s12272-021-01361-3","journal-title":"Arch Pharm Res"},{"issue":"6","key":"1366_CR11","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/j.1742-7843.2011.00751.x","volume":"109","author":"CI Choi","year":"2011","unstructured":"Choi CI, Kim MJ, Jang CG, Park YS, Bae JW, Lee SY (2011) Effects of the CYP2C9*1\/*13 genotype on the pharmacokinetics of lornoxicam. Basic Clin Pharmacol Toxicol 109(6):476\u2013480. https:\/\/doi.org\/10.1111\/j.1742-7843.2011.00751.x","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"1366_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00228-011-1098-0","volume":"68","author":"CI Choi","year":"2012","unstructured":"Choi CI, Kim MJ, Chung EK, Lee HI, Jang CG, Bae JW, Lee SY (2012) CYP2C9*3 and *13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects. Eur J Clin Pharmacol 68(2):149\u2013154. https:\/\/doi.org\/10.1007\/s00228-011-1098-0","journal-title":"Eur J Clin Pharmacol"},{"key":"1366_CR13","first-page":"57","volume-title":"Basic & clinical pharmacology","author":"MA Correia","year":"2021","unstructured":"Correia MA (2021) Drug biotransformation. In: Katzung BG, Vanderah TW (eds) Basic & clinical pharmacology, 15th edn. McGraw Hill, New York, pp 57\u201376","edition":"15"},{"issue":"2","key":"1366_CR14","doi-asserted-by":"publisher","first-page":"P45","DOI":"10.1016\/S0009-9236(03)90524-8","volume":"73","author":"R Courtney","year":"2003","unstructured":"Courtney R, Sansone A, Statkevich P, Martinho M, Laughlin M (2003) Assessment of the pharmacokinetic (PK), pharmacodynamic (PD) interaction potential between posaconazole and glipizide in healthy volunteers. Clin Pharmacol Ther 73(2):P45\u2013P45. https:\/\/doi.org\/10.1016\/S0009-9236(03)90524-8","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1366_CR15","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s13318-016-0383-9","volume":"42","author":"P Duan","year":"2017","unstructured":"Duan P, Zhao P, Zhang L (2017) Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin and atorvastatin to predict drug-drug interactions (DDIs). Eur J Drug Metab Pharmacokinet 42(4):689\u2013705. https:\/\/doi.org\/10.1007\/s13318-016-0383-9","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"9","key":"1366_CR16","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1080\/00498250500256367","volume":"35","author":"Y Guo","year":"2005","unstructured":"Guo Y, Wang Y, Si D, Fawcett PJ, Zhong D, Zhou H (2005a) Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica 35(9):853\u2013861. https:\/\/doi.org\/10.1080\/00498250500256367","journal-title":"Xenobiotica"},{"issue":"6","key":"1366_CR17","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1124\/dmd.105.003616","volume":"33","author":"Y Guo","year":"2005","unstructured":"Guo Y, Zhang Y, Wang Y, Chen X, Si D, Zhong D, Fawcett JP, Zhou H (2005b) Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos 33(6):749\u2013753. https:\/\/doi.org\/10.1124\/dmd.105.003616","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1366_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1365-2125.2005.02379.x","volume":"60","author":"A Holstein","year":"2004","unstructured":"Holstein A, Plaschke A, Ptak M, Egberts EH, El-Din J, Brockm\u00f6ller J, Kirchheiner J (2004) Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol 60(1):103\u2013106. https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02379.x","journal-title":"Br J Clin Pharmacol"},{"issue":"9\u201310","key":"1366_CR19","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s002280000214","volume":"56","author":"A J\u00f6nsson","year":"2000","unstructured":"J\u00f6nsson A, Chan JC, Rydberg T, Vaaler S, Hallengren B, Cockram CS, Critchley JA, Melander A (2000) Effects and pharmacokinetics of oral glibenclamide and glipizide in Caucasian and Chinese patients with type-2 diabetes. Eur J Clin Pharmacol 56(9\u201310):711\u2013714. https:\/\/doi.org\/10.1007\/s002280000214","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"1366_CR20","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s12272-020-01250-1","volume":"43","author":"EH Jung","year":"2020","unstructured":"Jung EH, Lee CM, Byeon JY, Shin HB, Oh KY, Cho CK, Lim CW, Jang CG, Lee SY, Lee YJ (2020a) Relationship between plasma exposure of zolpidem and CYP2D6 genotype in healthy Korean subjects. Arch Pharm Res 43(9):976\u2013981. https:\/\/doi.org\/10.1007\/s12272-020-01250-1","journal-title":"Arch Pharm Res"},{"issue":"12","key":"1366_CR21","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1007\/s12272-020-01300-8","volume":"43","author":"EH Jung","year":"2020","unstructured":"Jung EH, Lee YJ, Kim DH, Kang P, Lim CW, Cho CK, Jang CG, Lee SY, Bae JW (2020b) Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes. Arch Pharm Res 43(12):1356\u20131363. https:\/\/doi.org\/10.1007\/s12272-020-01300-8","journal-title":"Arch Pharm Res"},{"key":"1366_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-021-01363-1","author":"EH Jung","year":"2021","unstructured":"Jung EH, Cho CK, Kang P, Park HJ, Lee YJ, Bae JW, Choi CI, Jang CG, Lee SY (2021) Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients. Arch Pharm Res. https:\/\/doi.org\/10.1007\/s12272-021-01363-1","journal-title":"Arch Pharm Res"},{"issue":"1","key":"1366_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/00008571-199902000-00010","volume":"9","author":"RS Kidd","year":"1999","unstructured":"Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT (1999) Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 9(1):71\u201380. https:\/\/doi.org\/10.1097\/00008571-199902000-00010","journal-title":"Pharmacogenetics"},{"issue":"3","key":"1366_CR24","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s12272-016-0861-2","volume":"40","author":"SH Kim","year":"2017","unstructured":"Kim SH, Kim DH, Byeon JY, Kim YH, Kim DH, Lim HJ, Lee CM, Whang SS, Choi CI, Bae JW, Lee YJ, Jang CG, Lee SY (2017) Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite. Arch Pharm Res 40(3):382\u2013390. https:\/\/doi.org\/10.1007\/s12272-016-0861-2","journal-title":"Arch Pharm Res"},{"issue":"3","key":"1366_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s12272-018-1005-7","volume":"41","author":"MJ Kim","year":"2018","unstructured":"Kim MJ, Byeon JY, Kim YH, Kim SH, Lee CM, Jung EH, Chae WK, Lee YJ, Jang CG, Lee SY, Choi CI (2018a) Effect of the CYP2D6*10 allele on the pharmacokinetics of clomiphene and its active metabolites. Arch Pharm Res 41(3):347\u2013353. https:\/\/doi.org\/10.1007\/s12272-018-1005-7","journal-title":"Arch Pharm Res"},{"issue":"1","key":"1366_CR26","doi-asserted-by":"publisher","first-page":"12405","DOI":"10.1038\/s41598-018-30841-8","volume":"8","author":"SH Kim","year":"2018","unstructured":"Kim SH, Byeon JY, Kim YH, Lee CM, Lee YJ, Jang CG, Lee SY (2018b) Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes. Sci Rep 8(1):12405. https:\/\/doi.org\/10.1038\/s41598-018-30841-8","journal-title":"Sci Rep"},{"issue":"7","key":"1366_CR27","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s12272-021-01346-2","volume":"44","author":"YH Kim","year":"2021","unstructured":"Kim YH, Kang P, Cho CK, Jung EH, Park HJ, Lee YJ, Bae JW, Jang CG, Lee SY (2021) Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism. Arch Pharm Res 44(7):713\u2013724. https:\/\/doi.org\/10.1007\/s12272-021-01346-2","journal-title":"Arch Pharm Res"},{"issue":"1","key":"1366_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clpt.2004.08.009","volume":"77","author":"J Kirchheiner","year":"2005","unstructured":"Kirchheiner J, Brockm\u00f6ller J (2005) Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 77(1):1\u201316. https:\/\/doi.org\/10.1016\/j.clpt.2004.08.009","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1366_CR29","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1067\/mcp.2002.122476","volume":"71","author":"J Kirchheiner","year":"2002","unstructured":"Kirchheiner J, Brockm\u00f6ller J, Meineke I, Bauer S, Rohde W, Meisel C, Roots I (2002) Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 71(4):286\u2013296. https:\/\/doi.org\/10.1067\/mcp.2002.122476","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1366_CR30","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.2165\/00003088-200544120-00002","volume":"44","author":"J Kirchheiner","year":"2005","unstructured":"Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockm\u00f6ller J (2005) Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 44(12):1209\u20131225. https:\/\/doi.org\/10.2165\/00003088-200544120-00002","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1366_CR31","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00228-014-1641-x","volume":"70","author":"J Klen","year":"2014","unstructured":"Klen J, Dol\u017ean V, Jane\u017e A (2014) CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients. Eur J Clin Pharmacol 70(4):421\u2013428. https:\/\/doi.org\/10.1007\/s00228-014-1641-x","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1366_CR32","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1007\/s12272-015-0580-0","volume":"38","author":"YJ Lee","year":"2015","unstructured":"Lee YJ, Byeon JY, Kim YH, Kim SH, Choi CI, Bae JW, Sohn UD, Jang CG, Lee J, Lee SY (2015) Effects of CYP2C9*1\/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects. Arch Pharm Res 38(6):1232\u20131237. https:\/\/doi.org\/10.1007\/s12272-015-0580-0","journal-title":"Arch Pharm Res"},{"issue":"11","key":"1366_CR33","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00228-018-2522-5","volume":"74","author":"HI Lee","year":"2018","unstructured":"Lee HI, Byeon JY, Kim YH, Lee CM, Choi CI, Jang CG, Bae JW, Lee YJ, Lee SY (2018) Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites. Eur J Clin Pharmacol 74(11):1417\u20131426. https:\/\/doi.org\/10.1007\/s00228-018-2522-5","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"1366_CR34","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s12272-019-01201-5","volume":"42","author":"CM Lee","year":"2019","unstructured":"Lee CM, Jung EH, Byeon JY, Kim SH, Jang CG, Lee YJ, Lee SY (2019) Effects of steady-state clarithromycin on the pharmacokinetics of zolpidem in healthy subjects. Arch Pharm Res 42(12):1101\u20131106. https:\/\/doi.org\/10.1007\/s12272-019-01201-5","journal-title":"Arch Pharm Res"},{"issue":"2 Suppl 1","key":"1366_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/0026-0495(87)90195-8","volume":"36","author":"A Melander","year":"1987","unstructured":"Melander A (1987) Clinical pharmacology of sulfonylureas. Metabolism 36(2 Suppl 1):12\u201316. https:\/\/doi.org\/10.1016\/0026-0495(87)90195-8","journal-title":"Metabolism"},{"issue":"6","key":"1366_CR36","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1067\/mcp.2001.115822","volume":"69","author":"M Niemi","year":"2001","unstructured":"Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivist\u00f6 KT (2001) Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 69(6):400\u2013406. https:\/\/doi.org\/10.1067\/mcp.2001.115822","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1366_CR37","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1067\/mcp.2002.127495","volume":"72","author":"M Niemi","year":"2002","unstructured":"Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivist\u00f6 KT (2002) Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 72(3):326\u2013332. https:\/\/doi.org\/10.1067\/mcp.2002.127495","journal-title":"Clin Pharmacol Ther"},{"key":"1366_CR38","unstructured":"Pfizer Inc (2008) Glucotrol\u00ae (glipizide) U.S Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/017783s019lbl.pdf. Accessed 3 Nov 2021"},{"issue":"6","key":"1366_CR39","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1592\/phco.27.6.825","volume":"27","author":"A Sansone-Parsons","year":"2007","unstructured":"Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG (2007) Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmcotherapy 27(6):825\u2013834. https:\/\/doi.org\/10.1592\/phco.27.6.825","journal-title":"Pharmcotherapy"},{"issue":"11","key":"1366_CR40","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s12272-020-01294-3","volume":"43","author":"HB Shin","year":"2020","unstructured":"Shin HB, Jung EH, Kang P, Lim CW, Oh KY, Cho CK, Lee YJ, Choi CI, Jang CG, Lee SY, Bae JW (2020) ABCB1 c.2677G>T\/c.3435C>T diplotype increases the early-phase oral absorption of losartan. Arch Pharm Res 43(11):1187\u20131196. https:\/\/doi.org\/10.1007\/s12272-020-01294-3","journal-title":"Arch Pharm Res"},{"issue":"7","key":"1366_CR41","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/01.fpc.0000114749.08559.e4","volume":"14","author":"D Si","year":"2004","unstructured":"Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D (2004) Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 14(7):465\u2013469. https:\/\/doi.org\/10.1097\/01.fpc.0000114749.08559.e4","journal-title":"Pharmacogenetics"},{"issue":"2","key":"1366_CR42","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.diabres.2005.09.019","volume":"72","author":"K Suzuki","year":"2006","unstructured":"Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M (2006) Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract 72(2):148\u2013154. https:\/\/doi.org\/10.1016\/j.diabres.2005.09.019","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"1366_CR43","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00228-009-0736-2","volume":"66","author":"B Tan","year":"2010","unstructured":"Tan B, Zhang YF, Chen XY, Zhao XH, Li GX, Zhong DF (2010) The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects. Eur J Clin Pharmacol 66(2):145\u2013151. https:\/\/doi.org\/10.1007\/s00228-009-0736-2","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1366_CR44","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/s0378-4347(00)81560-1","volume":"164","author":"E W\u00e5hlin-Boll","year":"1979","unstructured":"W\u00e5hlin-Boll E, Melander A (1979) High-performance liquid chromatographic determination of glipizide and some other sulfonylurea drugs in serum. J Chromatogr 164(4):541\u2013546. https:\/\/doi.org\/10.1016\/s0378-4347(00)81560-1","journal-title":"J Chromatogr"},{"issue":"4","key":"1366_CR45","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2165\/00003088-198207040-00006","volume":"7","author":"E W\u00e5hlin-Boll","year":"1982","unstructured":"W\u00e5hlin-Boll E, Alm\u00e9r LO, Melander A (1982) Bioavailability, pharmacokinetics and effects of glipizide in type2 diabetics. Clin Pharmacokinet 7(4):363\u2013372. https:\/\/doi.org\/10.2165\/00003088-198207040-00006","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1366_CR46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/00000441-198907000-00012","volume":"298","author":"G Wensing","year":"1989","unstructured":"Wensing G (1989) Glipizide: an oral hypoglycemic drug. Am J Med Sci 298(1):69\u201371. https:\/\/doi.org\/10.1097\/00000441-198907000-00012","journal-title":"Am J Med Sci"},{"issue":"5","key":"1366_CR47","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ejps.2004.01.005","volume":"21","author":"D Wexler","year":"2004","unstructured":"Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M (2004) Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 21(5):645\u2013653. https:\/\/doi.org\/10.1016\/j.ejps.2004.01.005","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"1366_CR48","doi-asserted-by":"publisher","first-page":"18063","DOI":"10.1038\/s41598-018-36212-7","volume":"8","author":"F Yang","year":"2018","unstructured":"Yang F, Liu L, Chen L, Liu M, Liu F, Xiong Y, Hu X, Xia C (2018) OATP1B3 (699G>A) and CYP2C9*2, *3 significantly influenced the transport and metabolism of glibenclamide and glipizide. Sci Rep 8(1):18063. https:\/\/doi.org\/10.1038\/s41598-018-36212-7","journal-title":"Sci Rep"},{"issue":"4","key":"1366_CR49","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.clpt.2005.06.006","volume":"78","author":"OQ Yin","year":"2005","unstructured":"Yin OQ, Tomlinson B, Chow MS (2005) CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. Clin Pharmacol Ther 78(4):370\u2013377. https:\/\/doi.org\/10.1016\/j.clpt.2005.06.006","journal-title":"Clin Pharmacol Ther"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-021-01366-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-021-01366-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-021-01366-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T05:03:00Z","timestamp":1646283780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-021-01366-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,24]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1366"],"URL":"https:\/\/doi.org\/10.1007\/s12272-021-01366-y","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,24]]},"assertion":[{"value":"30 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}